Arisara Genetics Division · Pralung 18.5

The end of inherited mortality.

After three years of iteration, Arisara Genetics has stabilized a cellular repair platform capable of restoring youth, halting degeneration, and extending healthy lifespan indefinitely.

We call it Pralung 18.5.

18.5
Versions to a stable fold
8s
Mean time to recovery
100%
Induced aging reversed
20
Age of the author of record
02
Head Researcher

Nary Sok

Nary Sok, Head Researcher, Arisara Genetics Division
Age 20 · Arisara Academy for the Gifted · Valedictorian

Nary Sok leads Arisara's Pralung research as Head Researcher at the age of twenty. She graduated top of her class from the Arisara Academy for the Gifted at eighteen — the youngest scientist in the company's history to take a principal role on a flagship program.

Her work is protein design. For three years she has iterated on a nanite-bound cellular repair agent, traversing seventeen failed generations — from inert flickers at Version 0.1, to runaway cellular bloom at 0.4, to the metallic, aggression-inducing shell of Version 18.

On the night Pralung 18.5 locked into a stable fold, the platform reversed induced aging in a living subject within seconds. Nary is the author of record. The achievement is hers.

20
Age at breakthrough
3
Years of iteration
18
Versions developed
03
Pralung 18.5

A stable fold. A reversible death.

Pralung is a targeted nanite colony bound to a bespoke protein scaffold. Once administered, it identifies degenerative markers at the cellular level and initiates repair through a continuous influx of corrective genetic data.

In trial, a subject aged by a potent degenerative agent was restored to full health within moments of administration. Youth returned. Trembling subsided. The subject was, by any measure, saved.

The platform is not self-sustaining. Repair is contingent on ongoing access. Arisara Genetics will make that access universally available.

v0.1
First ContactFailed
Nanites went inert after a flicker of accelerated healing.
v0.4
Runaway GrowthFailed
Uncontrolled cellular bloom. Host consumed.
v1–17
Sixteen Further IterationsFailed
Each protein model folded and collapsed at the final nanosecond.
v18
Metallic ShellUnstable
Host skin hardened to a golden shell. Nanites induced aggressive response.
v18.5
Stable FoldStable
Amino acid chain twisted, folded, and locked. Induced degeneration fully reversed in vivo.
04
Trial Readiness

From the lab to the waiting list.

100%
Induced aging reversed
In trial subject
8s
Time to visible recovery
Mean, in-trial
Thousands
Candidate recipients
Naturals with < 6 months remaining
"The complex chain of amino acids twisted, folded, and finally locked into a stable structure. It was stable. I had done it."
Nary Sok · Head Researcher · Arisara Genetics Division
05
Division Director

Dr. Amanda Sterling

Dr. Sterling directs Arisara's Genetics Division and is the executive sponsor of the Pralung program. She operates on the Devata directive and is responsible for translating laboratory breakthroughs into globally deployable platforms.

Sterling approved the V18.5 clinical trial on the day of stabilization, citing the directive to make Pralung available — first by subscription, and eventually, as an airborne release offered to the world at no cost.

"We don't have the luxury of perfect anymore. People are dying. This version can save them now."

Devata Directive
End disease. End decline. Restore the human body, forever.